P1389: RUXOLITINIB DEMONSTRATES A GREATER CORTICOSTEROID-SPARING EFFECT THAN BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE

• R. Zeiser,
• D. Russo,
• R. Ram,
• S. Hashmi,
• R. Chakraverty,
• J. Moritz Middeke,
• S. Giebel,
• R. Sarkar,
• M. Gowda,
• S. Gunes,
• T. Stefanelli,
• S. J. Lee,
• T. Teshima,
• F. Locatelli

Affiliations

R. Zeiser

1 Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany

D. Russo

2 University of Brescia, ASST-Spedali Civili Brescia, Brescia, Italy

R. Ram

3 BMT Unit, Tel Aviv (Sourasky) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

S. Hashmi

4 Department of Medicine, Sheikh Shakhbout Medical City, Mayo Clinic, Abu Dhabi, United Arab Emirates

R. Chakraverty

5 UCL Cancer Institute, Institute of Immunity and Transplantation, London, United Kingdom

J. Moritz Middeke

6 Universitätsklinikum “Carl Gustav Carus” der Technischen Universität Dresden, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany

S. Giebel

7 The Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

R. Sarkar

8 Novartis Healthcare PVT. LTD, Hyderabad, India

M. Gowda

9 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

S. Gunes

10 Novartis Farma SPA, Lombardy, Italy

T. Stefanelli

11 Novartis Pharma AG, Basel, Switzerland

S. J. Lee

12 Fred Hutchinson Cancer Research Center, Seattle, United States of America

T. Teshima

13 Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan

F. Locatelli

14 Dipartimento di Oncoematologia Pediatrica, IRCCS, Ospedale Pediatrico Bambino Gesú, Sapienza, Università di Roma, Rome, Italy